| Literature DB >> 31105042 |
Behrouz Hassannia1, Peter Vandenabeele2, Tom Vanden Berghe3.
Abstract
One of the key challenges in cancer research is how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the main reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.Entities:
Keywords: GPX4; HMOX1; Iron; anti-cancer therapy; ferroptosis; lipid peroxidation; nanomedicine; p53
Year: 2019 PMID: 31105042 DOI: 10.1016/j.ccell.2019.04.002
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743